Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

FDA clears IND application for BXCL-501 for the treatment of opioid withdrawal symptoms

Feb. 6, 2020

Alkermes Pharma presents new naltrexone prodrugs for drug dependency

Feb. 5, 2020

Nr4a1 regulates gene transcription during cocaine abstinence: a potential target against addiction

Feb. 4, 2020

Naltrexone prodrugs synthesized at Alkermes

Jan. 31, 2020

Cerevel starts dosing volunteers in phase I study of CVL-936

Jan. 31, 2020

Snake venom organoid gives toxin insights

Jan. 30, 2020

Idorsia Pharmaceuticals discovers OX1/OX2 receptor antagonists

Jan. 29, 2020

Results from GLP preclinical study of AAV8-hCocH gene therapy

Jan. 22, 2020

Cobra genome may yield new antivenoms, venom-based drugs

Jan. 8, 2020

Opiant signs letter of intent with NCATS to collaborate on OPNT-004 development

Jan. 3, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...